CVM · Cel Sci Corp · Financials
$2.17
+0.08 (+3.59%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
Market Cap
$36.24M
Shares
17.59M
Volume · Oct 2
318.78K
Avg daily vol (3M)
241.58K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$264.03K
+65.5%
FY2014
Net Income
-$25.41M
+5.6%
FY2025
Operating Margin
-9721.4%
+2728.7pp
FY2014
Diluted EPS
-$6.27
+59%
FY2025
Operating Cash Flow
-$17.12M
+9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | $264.03K | $159.58K | $254.61K | $956.15K | — | — | |
| -$444.02K | -$648.94K | -$745.67K | — | -$1.08M | -$1.15M | -$1.04M | -$1.8M | — | — | -$1.88M | -$1.96M | -$1.93M | — | — | — | — | — | |
| $14.8M | $15.89M | $18.16M | $22.47M | $25.36M | $23.11M | $17.84M | $12.66M | $10.91M | $15.61M | $17.45M | $19.19M | $15.27M | $12.68M | $10.37M | $11.75M | $11.91M | $6.01M | |
| $7.49M | $8.92M | $8.19M | $9M | $10.71M | $13.09M | $11.7M | $8M | $6.33M | $5.8M | $6.49M | $13.86M | $10.67M | $6.98M | $6.6M | $6.66M | $6.29M | $5.67M | |
| $20K | $27K | $32K | $38K | $30.79K | $0 | $53K | $45K | $75K | $40K | $38K | $40.47K | $42.79K | $88.21K | $86.3K | $84.14K | — | — | |
| $2M | $2.06M | $2.14M | $2.11M | $1.98M | $447K | $389K | $588K | $575K | $593K | $626K | $680K | $703K | $275.92K | $447.17K | $531.32K | $516.12K | $417.21K | |
| $22.29M | $24.81M | $26.35M | $31.48M | $36.06M | $36.19M | $29.54M | $20.66M | $17.25M | $21.41M | $23.93M | $33.05M | $25.93M | $20.03M | $17.5M | $18.94M | $18.71M | $12.1M | |
| -$22.29M | -$24.81M | -$26.35M | -$31.48M | -$36.06M | -$36.19M | -$28.99M | -$20.2M | -$16.77M | -$21.41M | -$23.65M | -$32.39M | -$25.67M | -$19.87M | -$17.24M | -$17.99M | -$18.56M | -$12.02M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -9721.4% | -12450.12% | -6772.26% | -1881.04% | — | — | |
| -$20.29M | -$22.75M | -$24.22M | -$29.36M | -$34.09M | -$35.75M | -$28.6M | -$19.61M | -$16.2M | -$20.81M | -$23.02M | -$31.71M | -$24.96M | -$19.59M | -$16.8M | -$17.45M | -$18.04M | -$11.6M | |
| $445K | $649K | $746K | $675.42K | $1.08M | — | $1.2M | — | — | — | — | $129.99K | $163.77K | $170.42K | $262.21K | $322.98K | $162.33K | -$397.92K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $116.06K | $164.16K | $362.24K | $0 | |
| $25.83K | $47.63K | $177.68K | -$42.81K | $107.15K | -$8213 | $38.76K | — | — | — | -$1.88M | -$1.96M | -$40.92K | -$53.34K | -$146.15K | -$158.82K | — | — | |
| — | — | — | $0 | $615 | $5621 | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$34.87M | — | — | — | — | — | -$30.26M | -$22.13M | — | — | — | — | — | — | — | — | — | — | |
| -$22.7M | -$25.41M | -$26.92M | -$32.37M | -$36.7M | -$36.36M | -$30.26M | -$22.13M | -$31.84M | -$14.36M | -$11.51M | -$34.69M | -$27.35M | -$9.17M | -$15.48M | -$25.71M | $10.48M | -$40.91M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -10359.57% | -5746.82% | -6078.83% | -2689.14% | — | — | |
| -$22.7M | -$25.41M | -$27.58M | -$32.37M | -$37.63M | -$36.71M | -$30.28M | -$22.13M | -$31.85M | -$14.43M | -$11.51M | -$34.69M | -$28.47M | -$9.23M | -$17.65M | -$26.78M | $8.95M | -$41.4M | |
| USD/shares | — | — | — | — | -$26.10 | -$27.00 | -$24.60 | -$21.30 | -$56.10 | -$54.90 | -$71.10 | -$315.30 | -$363.00 | -$9.00 | -$21.00 | -$38.40 | $1.20 | -$9.30 |
| USD/shares | -$1.15 | -$6.27 | -$15.31 | -$21.90 | -$26.10 | -$27.00 | -$24.60 | -$21.30 | -$56.10 | -$57.30 | -$71.10 | -$315.30 | -$366.30 | -$19.80 | -$23.40 | -$44.70 | -$1.80 | -$9.30 |
| shares | — | — | — | — | 1.44M | 1.36M | 1.23M | 1.04M | 566.82K | 263.06K | 162.21K | 110.03K | 78.41K | 1.01M | 8.39M | 6.95M | 6.74M | 4.45M |
| shares | — | 4.06M | 1.8M | 1.48M | 1.44M | 1.36M | 1.23M | 1.04M | 566.82K | 263.42K | 162.21K | 110.03K | 78.41K | 1.01M | 8.39M | 6.95M | 6.74M | 4.45M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.79×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.31×
Peer medians compare against the 279 similar-size Biotechnology companies (of 532 listed).